![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 33, 25672-25680, August 18, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 3, 2000, and in revised form, April 13, 2000
Vitamin E ( Vitamin E is a physiological component of cellular membranes and
lipoproteins. Since its discovery in 1922 by Evans and Bishop (1),
researchers have confirmed the significance of Nutrition-related vitamin E deficiency in humans is a rare situation,
although several lines of evidence support a relationship between low
levels of If a binding protein is needed for Using radioactively labeled Materials--
Tritiated D- Preparation of Bovine Liver Cytosol--
Bovine liver was
obtained from freshly slaughtered calves. The liver was perfused with a
physiological NaCl solution, divided into portions, and frozen at
Gel Filtration--
For gel filtration 80 ml of cytosol was
mixed with 5 µCi of Affinity Chromatography--
The pooled tocopherol binding
fractions from the gel filtration were incubated while stirring
overnight at 4 °C with 2.5 µCi of
Ion Exchange Chromatography--
A Mono S HR 5/20 column
(Amersham Pharmacia Biotech) was equilibrated with 0.02 M
sodium phosphate, pH 6.5 (buffer B) at 4 °C. The pooled fractions
from the first radioactive peak of the Affi-Gel Blue chromatography
were concentrated and equilibrated with buffer B by ultrafiltration
using Centriplus 10 concentrators (Amicon Inc., Beverly, MA) to 4 ml.
After incubation for 1 h with 2.5 µCi of
Photographic Cross-linking--
Protein fractions
containing radioactive tocopherol were irradiated for 30 s in a
self-made device consisting of a 1-ml quartz cuvette, cooled to
4 °C, and placed at a 5-cm distance to a 150-watt xenon lamp.
Gel Electrophoresis, Isoelectric Focusing, and
Fluorography--
The purity of the
Reversed-phase HPLC--
For the final purification of TAP and
also for the separation of peptide digests, obtained by cyanogen
bromide cleavage, reversed-phase HPLC was performed. The samples were
adjusted with distilled water to 50 µl and loaded onto a Nova-Pak C4
reversed-phase column (Millipore Corp.). A linear acetonitrile gradient
(0-100%, 0.1% trifluoroacetic acid) at a flow of 0.5 ml/min
was used for the separations. Elution of proteins or peptides was
detected at 225 nm in the UV channel and at the same time at 280-nm
excitation and 320-nm emission in the fluorescent channel. Fractions of
0.5 ml were taken, and the samples were lyophilized in a Speedvac
concentrator (Savant, Munich, Germany).
Cyanogen Bromide Cleavage--
Mono S fractions containing the
highest radioactivity were desalted and concentrated to 30 µl with
Microcon 10 microconcentrators (Amicon Inc.) and mixed with 470 µl of
8 M urea, 0.4 M ammonium bicarbonate, pH 8.0. Reduction was achieved by 15-min incubation at 55 °C in the presence
of 25 µl of 100 mM dithiothreitol. For carboxyamidation, 20 µl of 0.5 M iodoacetamide was
added and the sample was kept for 15 min at room temperature in the
dark. The sample was dissolved to 1 ml with distilled water and again
concentrated to 30 µl. After adding 70 µl of 100% formic acid, the
sample was cleaved with 3 µl of 5 M CNBr under nitrogen
for 24 h in the dark. To remove formic acid the sample was exposed
to a nitrogen flow for 30 min.
Amino Acid Sequencing of Peptide Fragments and Homology
Search--
The isolated peptides were sequenced by automated Edman
degradation using a pulsed liquid-phase sequencer 477A on line with a
phenylthiohydantoin analyzer (PE Applied Biosystems, Foster City, CA).
The obtained amino acid sequences were analyzed with the EMBL/GenBankTM
data bases. The BLAST algorithm was used to search for proteins
homologous to bovine TAP.
Cloning of Human and Bovine TAP--
The coding area of the
cDNA for human TAP was amplified by RT-PCR using total
RNA from human small colon as template. Oligonucleotide primers were
synthesized based on the genomic TAP sequence with a sense
oligonucleotide primer (5'-ATGAGCGGCAGAGTCGGCGA-3') and an antisense
oligonucleotide primer (5'-TTATTTCGGGGTGCCTGCCCCCA-3') (Microsynth,
Balgach, Switzerland). PCR was carried out by using the GeneAmp RNA PCR
Kit (Perkin-Elmer) in a GeneAmp PCR System 9700 (PE Applied
Biosystems). RT-PCR conditions were: reverse transcription for 15 min
at 42 °C, denaturation for 5 min at 99 °C, and cooling for 5 min
at 5 °C. Half of the resulting cDNA was subjected to 40 cycles
of PCR under the following conditions: 30 s at 94 °C, 30 s
at 68 °C, and 90 s at 72 °C. 1 ng of the obtained cDNA
was used for reamplification in 30 cycles under the same conditions.
The resulting PCR product was purified with the JETsorb gel extraction
kit (Genomed, Bad Oeynhausen, Germany) and subcloned into the pGEM-T
vector (Promega, Madison, WI). The construct was transformed into JM101
competent cells using electroporation with 1800 V, 25 microfarads, and
200 ohms in a Gene Pulser II electroporation system (Bio-Rad). Clones
were sequenced using M13 forward and reverse oligonucleotide primers
(Microsynth), and sequence analysis was done using the Wisconsin
Sequence Analysis Package (version 9.1).
Bovine TAP was cloned using primers designed from the human
sequence. Total RNA from bovine liver was purified using the RNeasy Mini Kit (Qiagen, Basel, Switzerland). RT-PCR and PCR were performed as
described above with a sense oligonucleotide primer
(5'-ATGAGCGGCAGAGTCGGCGA-3') and an antisense oligonucleotide primer
(5'-GTCTGGAAGCAGGACCTCCAC-3') (Microsynth). PCR products were subcloned
as described above.
Human RNA Dot Blot and Northern Blot Analysis of Human
TAP--
Full-length human TAP cDNA was labeled with
[32P]dATP using a random primed DNA labeling kit (Roche
Molecular Biochemicals). For dot blot analysis, the probe was
hybridized with a blot containing poly(A)+ RNA from 50 different human tissues immobilized on a positively charged nylon
membrane (CLONTECH Laboratories, Heidelberg,
Germany). The hybridization was carried out as described in the user
manual. For Northern blot analysis of human TAP, a multiple tissue blot (CLONTECH) was probed under high stringency
conditions in accordance with the manufacturer's instructions.
Cloning of His-hTAP--
For protein expression of human
TAP, a construct containing a 6-histidine-tag (His) on the
carboxyl-terminal site was designed. The antisense oligonucleotide
primer for the PCR encoded the hexahistidine residue, the stop codon,
and an EcoRI restriction site
(5'-CCGGAATTCTCAGTGGTGGTGGTGGTGGTGTTTCGGGGTGCCTGCCCCCA-3'). The sense oligonucleotide primer contained an NdeI
restriction site and the start codon
(5'-ACAGGGAATTCCATATGAGCGGCAGAGTCGGCGA-3'). Cloned hTAP was
used as template. The resulting PCR product was subcloned into the
pGEM-T easy vector (Promega) and analyzed as described above. To be
able to induce protein expression, the His-hTAP cDNA was
subcloned into the expression vector pET 29b using the restriction
sites for NdeI and EcoRI and then transformed into Escherichia coli BL21.
In Vitro Expression and Purification of Human His-hTAP--
For
protein overexpression the His-hTAP/pET 29b construct was transformed
into E. coli BL21-CodonPlus(DE3)-RIL (Stratagene, La Jolla,
CA). Cells were grown in a liquid culture to an
A600 of 0.6-1.0, and the expression of
His-hTAP was induced with 1 mM
isopropylthiogalactopyranoside for 3 h. Cells were harvested by
centrifugation at 5000 × g for 5 min and resuspended
in 32 ml of ice-cold binding buffer (5 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9). For
disruption of the cells, a French press with a pressure of 1000 p.s.i. was used. The lysate was centrifuged at 39,000 × g for 20 min to remove debris. The supernatant fraction containing solubilized His-hTAP was used in affinity chromatography with His·Bind resin (Novagen). A 2.5-ml column was run with 0.5 ml/min, and fractions of 1 ml were collected. Purification of His-hTAP
was achieved in general as described in the user manual using imidazole
for protein elution. His-hTAP was eluted using 200 mM
imidazole in elution buffer (200 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9), and the
collected fractions were neutralized using 1 ml of 80 mM
Tris-HCl, pH 7.0, 20% glycerol. For the detection of His-hTAP protein,
an anti-His6 mouse monoclonal antibody (Roche Molecular
Biochemicals) was used together with the enhanced chemiluminescence system (Amersham Pharmacia Biotech) in accordance to the manufacturers.
Determination of Binding Constants Using the IASys
Biosensor--
An IASys single channel resonant mirror biosensor
(Fisons Applied Sensor Technology, Cambridge, UK) (27, 28) was used to
measure the kinetic constants and affinity of His-hTAP to a biotinylated
Avidin (200-µg excess) was coupled to a sensing cuvette manufactured
with a biotin layer, and biotinylated tocopherol (3-µg excess) was
then coupled to the immobilized avidin. Binding of tocopherol was
performed in phosphate-buffered saline containing 10% dimethyl
sulfoxide. Phosphate-buffered saline buffer, pH 7.2, was used for all
other binding reactions. The reaction vessel was stirred continuously
with the aid of a propeller. Binding was measured at 2-s intervals, and
the data readout from the biosensor was measured in units of
arc-seconds. The reactions were routinely followed for at least 5 min.
The kon value for each binding experiment, as
well as the kinetic constants, were calculated using the "Fast Fit"
program (Fisons Applied Sensor Technology) (29).
Replacement of His-hTAP Bound [3H]- Purification of Bovine Tocopherol-associated Protein, TAP--
The
identification of the novel cytosolic tocopherol-binding protein was
obtained by a modification of a previously shortly published protocol
(25). The preparation of hepatic cytosol and the first purification
step were performed in accordance to Kuhlenkamp et al. (30).
Hepatic cytosol was incubated with
The Cyanogen Bromide Cleavage and Peptide Identification--
Because
direct sequencing of the amino-terminal end by automated Edman
degradation failed, a cyanogen bromide cleavage of bovine TAP was
performed. This was followed by reversed-phase HPLC using a C4 column
to separate the obtained peptide fragments. From the elution profile
two major peaks at 23 and 26 min were fractionated and sequenced. Their
Edman degradation analysis showed two sequences: EVLPSQRYNAHLVPEDGSL
and FEENYPETLKXLFIVGAP, representing two peptides of 19 and
18 amino acids, respectively.
Identification of the Human TAP Gene and Sequence
Homologies--
The obtained peptide sequences of bovine TAP were used
to search for known proteins in data banks using the BLAST sequence alignment program. Both bovine sequences matched with 84% and 83%
identity with a hypothetical protein of 403 amino acids having a
calculated molecular weight of 46,145. This hypothetical protein is
coded by a human gene that is deposited at the
EMBL/GenBankTM with accession number AL096881. Both
methionine residues responsible for cyanogen bromide cleavage of the
bovine protein were found to be conserved in the human sequence,
indicating that this protein represents the human subtype of bovine
TAP. The nucleotide sequence of human TAP derives from the Homo
sapiens PAC clone DJ130H16, which has been sequenced and mapped by
the Sanger Center chromosome 22 mapping group. The gene maps within
chromosome 22 in region 22q12.1-ter and consists of 12 exons. A
computational analysis indicated that human TAP is a homologue to a
variety of functionally unrelated proteins (Fig.
4). It was recognized that these proteins share structurally conserved elements constituting a hydrophobic lipid
binding pocket called CRAL_TRIO, the profile of which is deposited at the PFAM protein family data base (32).
Cloning of Bovine TAP--
To confirm that the gene, identified
through the data base analysis, represented the human homologue of
TAP, bovine TAP was cloned using the primers
coding for the human sequence. Using total RNA from bovine liver as
template for RT-PCR, a 1.1-kb fragment was obtained showing the
expected size according to the chosen primers. By cloning the 1.1-kb
fragment into the pGEM-T vector and subsequently sequencing, the
identity of the peptides obtained from cyanogen bromide cleavage of
bovine TAP was confirmed. A comparison of the protein sequences of the
bovine fragment of TAP with human TAP revealed a 95% homology
(alignment not shown).
Cloning of Human TAP--
To further study its body distribution,
hTAP was cloned and its cDNA was used for in vitro
expression and Northern analysis studies. RT-PCR was carried out using
total RNA from human intestine and primers containing the 3'- or 5'-end
sequence of human TAP. After reamplification the 1.2-kb
cDNA fragment was cloned into the pGEM-T vector. Sequence analysis
of the subcloned cDNA confirmed that the clone contained the entire
open reading frame of human TAP with a 100% identity on the
nucleotide sequence.
Tissue Distribution of Human TAP--
To assess the presence and
relative abundance of hTAP gene transcripts in human
tissues, a commercially available Multiple Tissue Expression Array
(CLONTECH) was used containing poly(A)+
mRNAs from 50 different human tissues. Hybridization was carried out with Cloning of His-hTAP, in Vitro Expression and Purification--
To
permit a convenient protein isolation of hTAP, we designed a construct
containing a His-tag with six carboxyl-terminal histidine residues. PCR
was carried out using an antisense oligonucleotide primer containing
the sequence of the His-tag, a stop codon, and an EcoRI
restriction site for ligation into the expression vector pET 29b. The
sense oligonucleotide primer contained an NdeI restriction site next to the start codon. The probe was subcloned into the expression vector pET 29b under the control of the T7lac
promoter, and the sequence of the construct was confirmed through
sequence analysis. The plasmid was transformed into the
BL21-CodonPlus(DE3)-RIL cell line, which contains an additional plasmid
coding for argU, ileY, and leuW tRNA
genes to avoid limitation of certain tRNA species (33). Overexpression
of the recombinant His-hTAP protein was induced with 1 mM
isopropylthiogalactopyranoside for 3 h, and protein expression was
confirmed by Western blot analysis using an anti-His6
antibody (Fig. 7B). After cell
disruption with a French press, the recombinant His-hTAP was located in
the soluble fraction. Purification of His-hTAP was achieved by affinity
chromatography using His·Bind resin charged with Ni2+
ions by stepwise increasing imidazole concentrations (Fig.
7A).
His-hTAP Binding to Biotinylated Replacement by Various Ligands for His-hTAP-bound
Strategy to Reveal the Existence of a New Tocopherol Binding by His-hTAP--
These findings are also compatible with an in vivo role of
hTAP in tocopherol-mediated intracellular functions. The specificity of
Analogy with CRAL Proteins--
The structural analysis of
hTAP indicates that it is a member of the widespread
SEC14-like protein family. All members of this family have a common
conserved lipid-binding domain called CRAL_TRIO. The
structural determinants of the CRAL_TRIO domain have been
identified by Sha et al. (34) by resolving the crystal structure of the phosphatidylinositol transfer protein from yeast (SEC14). The SEC14 gene product has been shown to play an
essential role in yeast Golgi function. The presence of an SEC14-like
lipid-binding domain in hTAP indicates that this region may be involved
in hTAP membrane localization. In contrast to SEC14 and
The possibility that hTAP represents an additional
Possible Function of hTAP--
The presence of hTAP expression in
almost all tissues, although in different amounts, is indicative of an
important general cellular function of this protein. Its lack in fetus
liver may suggest also an embryogenetic role.
The search for an hTAP function may be guided by results obtained with
analogous proteins. SEC14 has been suggested to play a role in
phospholipid exchange (37, 38). The GTP binding motive, found to be
present together with GTP binding in
TAP,3 is similar to what has
been described for the rat secretory protein (39). A GTP binding/GTPase
activity may be important to confer to hTAP regulation properties in
its Conclusions--
In conclusion, intracellular proteins with the
ability to bind and redistribute The competent help of Maria Feher is
gratefully acknowledged. We gratefully acknowledge the generous gift of
(S)-Trolox by Dr. K. Müller, Hoffmann-La Roche, Basel.
*
This study was made possible by the support of the Swiss
National Science Foundation, by a grant of the Henkel Corporation, and
by the Stiftung für die Ernährungsforschung in der Schweiz.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
¶
To whom correspondence should be addressed: Tel.:
41-31-631-4129; Fax: 41-31-631-3737; E-mail:
achim.stocker@mci.unibe.ch.
Published, JBC Papers in Press, May 26, 2000, DOI 10.1074/jbc.M000851200
2
A. Stocker and S. Zimmer, unpublished results.
3
A. Stocker, unpublished information.
The abbreviations used are:
A Novel Human Tocopherol-associated Protein
CLONING, IN VITRO EXPRESSION, AND
CHARACTERIZATION*
§,
§¶,
,
,
Institute of Biochemistry and Molecular
Biology, University of Bern, Bühlstrasse 28, 3012 Bern,
Switzerland, the
Institute of Biochemistry & Biophysics, Tehran
University, P. O. Box 13145-1384, Tehran, Iran, and the ** Institute for
General Microbiology, University of Bern, Balzerstrasse 4, 3012 Bern,
Switzerland
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-tocopherol) is an essential
dietary nutrient for humans and animals. The mechanisms involved in
cellular regulation as well as in the preferential cellular and tissue
accumulation of
-tocopherol are not yet well established. We
previously reported (Stocker, A., Zimmer, S., Spycher, S. E., and
Azzi, A. (1999) IUBMB Life 48, 49-55) the identification
of a novel 46-kDa tocopherol-associated protein (TAP) in the cytosol of
bovine liver. Here, we describe the identification, the molecular
cloning into Escherichia coli, and the in vitro
expression of the human homologue of bovine TAP, hTAP. This protein appears to belong to a family of
hydrophobic ligand binding proteins, which have the CRAL
(cis-retinal binding motif) sequence in common. By using a
biotinylated
-tocopherol derivative and the IASys resonant mirror
biosensor, the purified recombinant protein was shown to bind
tocopherol at a specific binding site with Kd
4.6 × 10
7 M. Northern analyses showed
that hTAP mRNA has a size of approximately 2800 base pairs and is
ubiquitously expressed. The highest amounts of hTAP message are found
in liver, brain, and prostate. In conclusion, hTAP has sequence
homology to proteins containing the CRAL_TRIO structural
motif. TAP binds to
-tocopherol and biotinylated tocopherol, suggesting the existence of a hydrophobic pocket, possibly analogous to
that of SEC14.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-tocopherol as the
principal vitamin E homologue in human plasma (2). Roles in the
maintenance of tissue integrity (3) in the prevention of
atherosclerosis (4) and prostate cancer (5) as well as in the
regulation of the immune response (6) have been proposed. Most of these
effects have been attributed to two primary functions of
-tocopherol. One function of
-tocopherol is as a scavenger of
reactive oxygen (7) and nitrogen species (8) able to break radical
chain propagation reactions (9). The other function of
-tocopherol,
more recently elucidated, is an additional role consisting of a
structure-specific modulation of cellular functions such as adhesion
(10), proliferation (11), and apoptosis (12). Decreased levels of
-tocopherol can thus evoke unspecific damage to lipid, protein, and
DNA caused by the unscavenged reactive oxygen and nitrogen species;
they can, at the same time, induce defined cellular responses, which
cannot be neutralized by
-tocopherol-related phenolic antioxidants
(13, 14). The latter events can be related to
-tocopherol-induced
protein kinase C inhibition (15), to the activation of the nuclear
transcription factor
B (16), and to the modulation of the expression
of specific genes, e.g. the gene of collagenase 1 (17), the gene of
-tropomyosin (18), and the gene for one of the
scavenger receptors (19). These cellular events require specific
recognition molecules that are able to bind tocopherol and feed this
information further into the cell signaling pathways. Furthermore, due
to its strong hydrophobicity and its primary location in the plasma
membrane,
-tocopherol requires a carrier mechanism, which can
regulate its cytosolic transport to other cellular sites. The mechanism
by which
-tocopherol is redistributed within the cell and reaches
mitochondria and the nucleus has not been studied.
-tocopherol and human diseases, e.g. increased risk of atherosclerosis and prostate cancer. Recently, a group of
patients having remarkably low levels of plasma
-tocopherol were
studied in Tunisia (20, 21). In these patients, a genetic defect of an
-tocopherol-specific liver protein
(
-TTP)1 caused the
disruption of tocopherol transfer from chylomicrons into plasma
lipoproteins and a clinical syndrome, AVED (ataxia with isolated
vitamin E deficiency). When these patients were given a high dose of
-tocopherol, the progression of the disease was reduced (22).
-tocopherol transfer from
chylomicrons via liver into plasma, it is important to ask if other
proteins might be responsible for the distribution of
-tocopherol to
intracellular compartments. Indeed a number of studies have been
carried out in an attempt to isolate and characterize such proteins
(23, 24).
-tocopherol as a tracer we have recently
identified and briefly described a new
-tocopherol binding protein
of molecular mass 46 kDa in the cytosol of bovine liver, which has been
called
-tocopherol-associated protein (TAP) (25). In this paper, we
present the identification, molecular cloning, and the in
vitro expression of the human homologue of TAP. The kinetic data
of the interaction between recombinant TAP and a biotinylated
tocopherol derivative are presented. In addition, the results of a
structural analysis of its lipid binding domain and studies on the
distribution of TAP in human tissues are reported.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-tocopherol (24.76 Ci/mmol) was synthesized by Amersham Pharmacia Biotech and further
purified on a Nova-Pak C18 HPLC column from Millipore Corp. (Bedford,
MA) using methanol/water (96/4, v/v) as the mobile phase and stored at
20 °C under nitrogen. The purity of
D-
-[3H]tocopherol was checked during the
course of the studies by HPLC and/or by thin layer chromatography. The
radioactivity was measured with a Packard liquid scintillation analyzer
(Tri-Carb 2100 TR) using Irga-Safe Plus from Packard (Meriden, CT). All
other analytical-grade chemicals were obtained from Sigma or Merck
(Darmstadt, Germany).
80 °C for future use. Thawed liver was homogenized using a
Polytron homogenizer (Kinematica GmbH, Switzerland) with 2 volumes of
homogenization buffer consisting of 0.01 M sodium
phosphate, pH 7.4, 0.25 M sucrose, and 1 mM
phenylmethylsulfonyl fluoride. All further purification steps were
carried out at 4 °C. The homogenate was centrifuged at 5000 × g for 15 min to remove crude particles and whole cells.
After ultracentrifugation of the supernatant at 140,000 × g for 90 min the obtained cytosol was stored in portions at
80 °C.
-[3H]tocopherol,
incubated while stirring for 2 h at 4 °C, and fractionated on a
5- x 80-cm Sephacryl S-200 gel column (Pharmacia Fine Chemicals, Uppsala, Sweden) using a 0.01 M sodium phosphate buffer, pH
7.4 (buffer A). Fractions of 10 ml were collected, and the
radioactivity of each fraction was measured.
-[3H]tocopherol. A 0.6- x 40-cm Affi-Gel Blue column
(Bio-Rad) was equilibrated with buffer A. The incubation mixture was
applied to the column, which was subsequently washed with 100 ml of the same buffer. Proteins were eluted with a linear NaCl gradient, consisting of 400 ml of buffer A and 400 ml of buffer A with 1.1 M NaCl and 2 mM EDTA. Fractions of 10 ml were
collected and monitored for radioactivity.
-[3H]tocopherol at 4 °C, the sample was applied to
the column and the column was washed with 5 ml of the same buffer. For
elution a linear NaCl gradient consisting of 12.5 ml of buffer B and
12.5 ml of buffer B with 1 M NaCl was run. Fractions of 1 ml were collected and monitored for radioactivity.
-[3H]tocopherol-containing fractions was tested by
SDS-PAGE (26), and gels were stained with Coomassie Brilliant Blue
R-250. Native isoelectric focusing was performed on Servalyt Precotes
3-10 precast gels as described by the manufacturer (Serva, Heidelberg,
Germany). Briefly, proteins were focused at 1500 V for 3500 volt-hours at 4 °C using 1 M NaOH as catholyte buffer and 1 M H3PO4 as anolyte
buffer. The gels were fixed with 20% trichloroacetic acid and stained
in Serva Violet 17. Fluorography was carried out by incubating the gels
for 30 min with 1 M sodium salicylate and subsequent drying
and exposure to Biomax mass spectrometry film (Eastman Kodak Co.).
-tocopherol derivative. The biotinylated
-tocopherol derivative was obtained by total synthesis, and its identity as 3,4-dihydro-2,5,7,8-tetramethyl-2-(tridecylamidopentyl)-19'-(biotinamid)-2H-1-benzopyran-6-ol was determined by 1H NMR and mass
spectrometry.2
-Tocopherol
with Aternate Ligands--
Radioactive
-[3H]tocopherol (7.9 µg) was dissolved in 100 µl
of water by addition of 2-hydroxypropyl-
-cyclodextrin (144 mg). The
unlabeled ligands were solubilized in water by
2-hydroxypropyl-
-cyclodextrin (144 mg in 100 µl) and adjusted to a
final concentration of 2.5 mM. The concentrations of the
dissolved unlabeled ligands were determined in water by UV
spectrophotometry. The dissolved radioactive tocopherol (135 µl) was
added to 100 µl of purified His-hTAP (10 mg/ml) in 10 mM
Tris, pH 7.4, and incubated overnight at 4 °C. From this mixture,
aliquots of 10 µl were added to 20 µl of the corresponding
nonlabeled ligand and incubated overnight at 4 °C. To this mixture,
600 µl of binding buffer (5 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9) containing 30 µl of His·Bind resin was added, and after shortly shaking the
mixture the resin was centrifuged at 14,000 × g for 1 min. The supernatant was carefully removed, and the resin was washed
sequentially in 1 ml of binding buffer and then in 1 ml of binding
buffer containing 2% BSA. The bound protein was eluted from the resin
by adding 1 ml of elution buffer (1 M imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9) containing 2%
BSA. After centrifugation, the amount of
-[3H]tocopherol bound to His-hTAP was determined in
the supernatant by scintillation counting.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-[3H]tocopherol and
fractionated by size-exclusion chromatography on a Sephacryl S-200
column. A radioactive protein peak corresponding to a molecular
mass range from 30 to 70 kDa was obtained (Fig. 1A). Further purification by
Affi-Gel Blue affinity chromatography revealed two radioactive protein
peaks (Fig. 1B). To prove that the radioactivity in both
peaks was associated with distinct proteins, native isoelectric
focusing was performed. Fractions from peak 1 showed a major
radioactive spot that corresponded to a protein with a pI of 8.1. The
fractions of peak 2 revealed a double signal focusing around a pI of
6.5 (Fig. 2A). Fractions of
both peaks were irradiated to covalently link the bound
-[3H]tocopherol to the corresponding proteins.
Subsequent fluorography revealed signals at 46 and at 31 kDa in
fractions from peaks 1 and 2, respectively (Fig. 2B).

View larger version (15K):
[in a new window]
Fig. 1.
Elution of
-[3H]tocopherol on Sephacryl S-200
gel filtration (A), Affi-Gel Blue affinity
chromatography (B), and ion exchange chromatography
(C). The horizontal bars indicate
pooled fractions used for further purification. Broken lines
show salt gradients. See "Experimental Procedures" for
details.

View larger version (52K):
[in a new window]
Fig. 2.
Fluorography of isoelectric focusing
(A) and photographic cross-linking
(B). Radioactive signals in lane 1 at
pI of 8.1 and 46 kDa show bTAP. The signals in lane 2 at pI
6.5 and 31 kDa show the hypothetical bovine tocopherol transfer
protein.
-tocopherol-transfer protein (
-TTP) from rat liver was shown
to have a molecular mass of 31 kDa with reported isoforms having pIs of
5.3 and 5.4 (31). This led to the conclusion that the 31-kDa protein
peak producing a double band at pI 6.5 represented the two isoforms of
the corresponding bovine subtype of
-TTP. Thus, the additional
protein contained in peak 1 had to be considered as a novel
-tocopherol-binding protein. Being the only function known of this
novel protein, i.e. that of associating
-tocopherol (used
as a purification criterion), it was named tocopherol-associated protein (TAP). Further purification of bovine TAP was achieved by cation exchange chromatography on a Mono S column (Fig.
1C). SDS-PAGE analysis of the fraction with the highest
radioactivity showed one predominant band at 46 kDa with minor
contaminating proteins (Fig.
3B). A final purification step
was performed by reversed-phase chromatography on a wide pore C4 column
(Fig. 3A). SDS-PAGE analysis revealed one single protein
band with an apparent molecular mass of 46 kDa (Fig. 3B).
The estimation of the molecular mass of the purified native protein by
gel filtration (data not shown) confirmed that bovine TAP was a
monomeric protein with an apparent molecular mass of 46 kDa.

View larger version (25K):
[in a new window]
Fig. 3.
Reversed-phase HPLC of bTAP containing
fractions from ion exchange chromatography. A, protein
was eluted on a C4 reversed-phase column with a linear acetonitrile
gradient (0-100%, 0.1% trifluoroacetic acid). B,
SDS-PAGE of purified bTAP (Coomassie staining). Lane S
indicates the fraction from Mono S purification; lanes 36,
37, 38, and 39 represent fractions
from the purification by reversed-phase chromatography.

View larger version (77K):
[in a new window]
Fig. 4.
Alignment of the CRAL_TRIO-domain
from human TAP with homologous proteins. Human TAP (amino acids
63-246; EMBL/GenBankTM accession number AL096881) has been aligned
with human cellular retinal-binding protein (J04213), human tyrosine
phosphatase (M83738), squid retinal-binding protein (S68871), 45-kDa
secretory protein from rat olfactory epithelium (AJ132352), yeast
phosphatidylinositol transfer protein (X15483), and human
-tocopherol transfer protein (D49488). Gaps (.) have been inserted
to demonstrate maximum sequence similarity. Residues identical or
showing conserved substitution with those of human TAP are indicated
with shaded letters. Conserved amino acid substitutions are
defined as pairs of residues belonging to one of the following groups:
S/T/P/A/G; N/D/E/Q; H/R/K; M/I/L/V; and F/Y/W.
-[32P]dATP-labeled cDNA of the human
TAP clone. Expression levels of target mRNA were
determined by analyzing the washed blot with a phosphor imager. The
results show a broad tissue distribution of mRNA for
hTAP with strong signals in liver, prostate, and brain tissues (Fig. 5A). To assess
the relative expression levels of mRNA the strongest signal on the
master blot was set to 100%, and all other signals were calculated as
a percentage of it (Fig. 5B). Signals showing an expression
level lower then 5% were neglected because of background variations.
In contrast to the broad tissue distribution of hTAP in
adult tissues, fetal tissues were found to have low expression levels
in the range of the background. Northern analysis using a multiple
tissue blot (CLONTECH) revealed one major mRNA
transcript of approximately 2.8 kb and two minor transcripts of
approximately 4.2 and 1.5 kb. The 2.8-kb transcript was found to be
strongly expressed in liver and brain and weakly expressed in kidney
(Fig. 6). The existence of a human 2.8-kb mRNA transcript (AL096881) encoding for a hypothetical protein with
homology to Rattus norvegicus 45-kDa secretory protein
(AJ132352) has been proposed recently. Based on these results and the
dot blot analysis described above, we conclude that the major mRNA transcript of hTAP has 2818 base pairs and is widely
expressed in human tissues, with the highest levels being found in
liver, brain, and prostate.

View larger version (40K):
[in a new window]
Fig. 5.
Multiple tissue expression analysis of
hTAP. A, autoradiogram of human RNA
master blot (CLONTECH) hybridized with a
32P-labeled cDNA of hTAP. B, dot-to-dot
variations are expressed as percentage of maximal intensity relative to
the liver tissue.

View larger version (62K):
[in a new window]
Fig. 6.
Northern analysis of hTAP. The size
distribution of the hTAP transcript was analyzed using a
human multiple tissue Northern blot (CLONTECH)
hybridized with a 32P-labeled cDNA of hTAP.

View larger version (54K):
[in a new window]
Fig. 7.
Analysis of purification of His-hTAP.
The purification of recombinant His-hTAP was followed by SDS-PAGE
(A) and Western blotting (B). Lane 1 shows the molecular weight standard, lanes 2 and
3 show the E. coli supernatants uninduced and
after induction. In the residual lanes the elution of pure
His-hTAP on Ni-NTA-Sepharose using 200 mM imidazole is
depicted.
-Tocopherol Derivative Using
the IASys Biosensor--
The interaction of His-hTAP with the
immobilized biotinylated
-tocopherol derivative was studied with the
IASys resonant mirror biosensor. In these experiments the biotin label
of the derivative was immobilized by binding to avidin coupled to the biotin surface of a cuvette, and the binding at different His-hTAP concentrations was monitored over a minimum 5-min period. As shown in
Fig. 8 the derivative consists of a
biotin label being attached by an amide bond to the tail of the
synthetic straight-chain R-
-tocopherol derivative. The
plots of the response observed following the addition of the indicated
concentrations of His-hTAP and BSA show that His-hTAP binds
significantly to the tocopherol derivative, whereas no significant
binding was observed with BSA (Fig.
9A). Comparing the plots at
different concentrations the binding of His-hTAP was found to be
concentration-dependent in the range of 100 nM to 5 µM. When the binding data for the interaction of
His-hTAP with immobilized tocopherol were fitted to the double
exponential curve, a linear relationship was observed between
kon and ligand concentration according to the
equation kon = kdiss + kass [ligand] (Fig. 9B). Using this
method, the kass (1.759 ± 0.113 × 103 M
1 s
1) and
kdiss (8.08 ± 2.46 × 10
4 s
1) values for the interaction are
given by the slope and y intercept of the plot,
respectively. Values of dissociation constants
(KD) were calculated from the relationship
KD = kdiss/kass. For the binding of TAP to the tocopherol derivative, the
KD value was calculated to be 4.6 × 10
7 M.

View larger version (16K):
[in a new window]
Fig. 8.
Biotinylated
-tocopherol derivative. The structure of total
synthetic biotinylated
-tocopherol, as confirmed by 1H
NMR and mass spectrometry; the proposed systematic name is given
underneath.

View larger version (9K):
[in a new window]
Fig. 9.
Interaction analysis of soluble His-hTAP with
the immobilized biotinylated
-tocopherol
derivative. A, comparison of the interaction of 100 µg of His-hTAP and 100 µg of BSA with immobilized, biotinylated
-tocopherol derivative via avidin, coupled to the biotin surface of
a cuvette. The measurements were made by an IASys resonant mirror
biosensor. A saturating response of 800 arc-seconds was observed for
His-hTAP, equivalent to 1.5 ng/mm2, according to the
information supplied by the manufacturer for planar cuvette surfaces.
B, determination of binding constants for the interaction of
His-hTAP with immobilized biotinylated
-tocopherol from three
separate experiments, using the IASys resonant mirror biosensor. For
each concentration of His-hTAP, the rate constants
(kon) were determined by the linearization
procedure using the Fast Fit program. The plot of
kon versus His-hTAP concentrations
gave a straight line with a slope representing
kass and the intercept with the y
axis equivalent to kdiss. The calculated
correlation coefficient for this data is 0.982.
-[3H]Tocopherol--
To assess the binding
specificity of His-hTAP for various forms of tocopherol and hydrophobic
ligands, replacement of
-[3H]tocopherol by a 64-fold
excess of each alternative ligand was determined. The results of Table
I represent the average of
duplicate experiments ± S.E. Tocopherols were the most efficient
species in replacing His-hTAP-bound
-[3H]tocopherol
followed by biotinylated
-tocopherol derivative. 3-sn-Phosphatidylcholine appeared to be without effect.
Replacement of His-hTAP bound
-[3H]tocopherol by various
ligands
-[3H]tocopherol bound to His-hTAP was
determined in the presence of 64-fold excess of the indicated ligands
as described under "Experimental Procedures." The replacement
factors have been calculated from the mean values ± S.E. taking
the value of 3-sn-phosphatidylcholine as 1.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Tocopherol-Binding
Protein--
The present study describes the finding, cloning, and
in vitro expression of the human gene encoding the
tocopherol-associated protein (hTAP). Initial investigations
on the cellular distribution of vitamin E have led to the
identification of a novel cytosolic protein (bTAP) from bovine liver
that binds radioactively labeled
-tocopherol. Peptide mapping of
bTAP revealed two peptide sequences matching with high homology to a
human gene encoding for a 403-amino acid protein of unknown function.
To obtain conclusive evidence for the hypothesis that this protein was
identical with the human subtype of bTAP a 1.1-kb fragment of the
bovine gene was amplified by RT-PCR using primers deriving from the
human gene and bovine RNA as template. The high degree (95%) of
sequence homology of the amplicon gave unequivocal evidence that this
gene represents the human subtype of bTAP.
-Tocopherol appears to be
specifically selected in the human body and exerts specific functions
uniquely related to its structure. The former event is performed by the
liver
-TTP; the latter are
-tocopherol exclusive actions at the
level of cell signal transduction that result in
-tocopherol-dependent gene expression. How does the
regulation of signal transduction and gene expression by
-tocopherol take place? Is there a need for a cellular protein recognizing
-tocopherol? To establish if hTAP may play such a role, the
interaction between the protein and tocopherol was investigated. The
technique employed simulates the in vivo situation where a
cytosolic protein (hTAP) accesses a hydrophobic surface (the membrane)
that contains
-tocopherol. A biotinylated
-tocopherol derivative
was immobilized and used as a ligand for the binding measurements
performed using an IASys-resonant mirror system and recombinant
His-hTAP. The biotinylated
-tocopherol has been shown (cf. Table I)
to bind with hTAP, as indicated by the competition experiments with
hTAP-bound radioactive
-tocopherol, although with a lower affinity.
The obtained data show a dose-dependent saturable binding
of His-hTAP to the biotinylated tocopherol, and at the same time they
have excluded the possibility of nonspecific interactions as shown by
the absence of binding of BSA. The data show a dissociation constant of
4.6 × 10
7 M. This suggests that the
recombinant His-hTAP is expressed with a functional lipid-binding
domain and that it binds to biotinylated tocopherol well within
physiological concentrations. However, the efficiency of cold
-tocopherol in competing with the hot hTAP-bound one is higher than
that of the biotinylated form. This indicates that the dissociation
constant obtained with this method is underestimated.
-tocopherol binding to hTAP has been studied by competition experiments between radioactive
-tocopherol bound to hTAP and a
number of hydrophobic molecules dissolved in the aqueous medium by
-cyclodextrin. The use of a radioactive assay, the only one available at the present moment, has limited the analysis to the question of tocopherol specificity in comparison with other ligands. Further studies on the relative affinity of the different tocopherols require the development of a more sensitive assay. However, it was
already possible to show that more
-tocopherol remains bound to the
His-hTAP when biotinylated tocopherol is used as a competitor. All
other tocopherols were equally effective at the concentrations used
(1.7 mM). A titration of the release of bound
-tocopherol at lower concentrations of other tocopherols would be
needed to establish their relative affinities, but the assay precision
does not permit this information to be obtained.
-TTP, the hTAP gene product
contains a unique 157-amino acid carboxyl-terminal extension. The
strong overall sequence homology of hTAP with the 45-kDa
secretory protein from rat (AJ132352), which also contains this
extension, indicates that both proteins are closely related. The 45-kDa
rat secretory protein is present in cells of the olfactory epithelium,
the apical region of the trachea, the surface layer of the ciliated
bronchial epithelium, and the epidermis (35). Opposite to this,
hTAP mRNA is ubiquitous and strongly expressed exclusively in adult tissues.
-tocopherol transfer protein cannot be excluded. However, in
contrast to
-TTP, which is present essentially only in the liver
(36), hTAP mRNA is ubiquitous and present in liver, in the
prostate, and in brain in larger amounts.
-TTP lacks the carboxyl
terminus domain, which suggests there is a different functional role
for hTAP. Affinity data of
-TTP that suggest a recognition of the different tocopherols and tocotrienols cannot yet be obtained for TAP,
although the latter can distinguish between tocopherols and other
hydrophobic ligands as well as biotinylated tocopherol.
-tocopherol redistribution function. Proteins having SEC14-like
domains can interact with ras21 and through this binding be
able to suppress ras21 activity (40).
-tocopherol as well as
-tocopherol receptor molecules appear to be needed to fully
understand the mechanism of action of this molecule. It is still too
early to state if hTAP is one or the other, but in either case hTAP may
be an important molecule (or a member of a family of molecules) capable
of binding
-tocopherol and responsible for important intracellular events.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
-TTP,
-tocopherol-transfer protein;
bTAP/hTAP, bovine/human
-tocopherol-associated protein;
CRAL, cis-retinal binding
motif;
SEC14, SEC14 cytosolic factor;
His-hTAP, histidine-tagged human
-tocopherol-associated protein;
IASys, interaction analysis system;
HPLC, high performance liquid chromatography;
RT-PCR, reverse
transcription-polymerase chain reaction;
PAGE, polyacrylamide gel
electrophoresis;
BSA, bovine serum albumin;
kb, kilobase(s).
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Evans, H. M.,
and Bishop, K. S.
(1922)
Science
55,
650-651
2.
Traber, M. G.,
and Kayden, H. J.
(1989)
Am. J. Clin. Nutr.
49,
517-526
3.
Karasu, C.,
Ozansoy, G.,
Bozkurt, O.,
Erdogan, D.,
and Omeroglu, S.
(1997)
Metabolism
46,
872-879
4.
Stephens, N. G.,
Parsons, A.,
Schofield, P. M.,
Kelly, F.,
Cheeseman, K.,
and Mitchinson, M. J.
(1996)
Lancet
347,
781-786
5.
Heinonen, O. P.,
Albanes, D.,
Virtamo, J.,
Taylor, P. R.,
Huttunen, J. K.,
Hartman, A. M.,
Haapakoski, J.,
Malila, N.,
Rautalahti, M.,
Ripatti, S.,
Maenpaa, H.,
Teerenhovi, L.,
Koss, L.,
Virolainen, M.,
and Edwards, B. K.
(1998)
J. Natl. Cancer Inst.
90,
440-446
6.
Meydani, S. N.,
Meydani, M.,
Blumberg, J. B.,
Leka, L. S.,
Siber, G.,
Loszewski, R.,
Thompson, C.,
Pedrosa, M. C.,
Diamond, R. D.,
and Stollar, B. D.
(1997)
JAMA
277,
1380-1386
7.
Burton, G. W.,
Joyce, A.,
and Ingold, K. U.
(1982)
Lancet
2,
327
8.
Vatassery, G. T.,
Smith, W. E.,
and Quach, H. T.
(1998)
J. Nutr.
128,
152-157
9.
Burton, G. W.,
Cheeseman, K. H.,
Doba, T.,
Ingold, K. U.,
and Slater, T. F.
(1983)
Ciba Found. Symp.
101,
4-18
10.
Wu, D.,
Koga, T.,
Martin, K. R.,
and Meydani, M.
(1999)
Atherosclerosis
147,
297-307
11.
Azzi, A.,
Boscoboinik, D.,
Clement, S.,
Ozer, N.,
Ricciarelli, R.,
and Stocker, A.
(1999)
Diabetes Res. Clin. Pract.
45,
191-198
12.
Straface, E.,
Santini, M. T.,
Donelli, G.,
Giacomoni, P. U.,
and Malorni, W.
(1995)
Int. J. Radiat. Biol.
68,
579-587
13.
Ozer, N. K.,
Sirikci, O.,
Taha, S.,
San, T.,
Moser, U.,
and Azzi, A.
(1998)
Free Radic. Biol. Med.
24,
226-233
14.
Pastori, M.,
Pfander, H.,
Boscoboinik, D.,
and Azzi, A.
(1998)
Biochem. Biophys. Res. Commun.
250,
582-585
15.
Azzi, A.,
Boscoboinik, D.,
Fazzio, A.,
Marilley, D.,
Maroni, P.,
Ozer, N. K.,
Spycher, S.,
and Tasinato, A.
(1998)
Z Ernaehrwiss
37(Suppl 1),
21-28
16.
Poynter, M. E.,
and Daynes, R. A.
(1999)
Cell. Immunol.
195,
127-136
17.
Ricciarelli, R.,
Maroni, P.,
Ozer, N.,
Zingg, J. M.,
and Azzi, A.
(1999)
Free Radic. Biol. Med.
27,
729-737
18.
Aratri, E.,
Spycher, S. E.,
Breyer, I.,
and Azzi, A.
(1999)
FEBS Lett.
447,
91-94
19.
Kolleck, I.,
Schlame, M.,
Fechner, H.,
Looman, A. C.,
Wissel, H.,
and Rustow, B.
(1999)
Free Radic. Biol. Med.
27,
882-890
20.
Ouahchi, K.,
Arita, M.,
Kayden, H.,
Hentati, F.,
Ben Hamida, M.,
Sokol, R.,
Arai, H.,
Inoue, K.,
Mandel, J. L.,
and Koenig, M.
(1995)
Nat. Genet.
9,
141-145
21.
Cavalier, L.,
Ouahchi, K.,
Kayden, H. J.,
Di Donato, S.,
Reutenauer, L.,
Mandel, J. L.,
and Koenig, M.
(1998)
Am. J. Hum. Genet.
62,
301-310
22.
Labauge, P.,
Cavalier, L.,
Ichalalene, L.,
and Castelnovo, G.
(1998)
Rev. Neurol. (Paris)
154,
339-341
23.
Brigelius-Flohe, R.,
and Traber, M. G.
(1999)
FASEB J.
13,
1145-1155
24.
Dutta-Roy, A. K.
(1997)
Methods Enzymol
282,
278-297
25.
Stocker, A.,
Zimmer, S.,
Spycher, S. E.,
and Azzi, A.
(1999)
IUBMB Life
48,
49-55
26.
Laemmli, U. K.
(1970)
Nature
227,
680-685
27.
Rubio, I.,
Buckle, P.,
Trutnau, H.,
and Wetzker, R.
(1997)
BioTechniques
22,
269-271
28.
George, A. J.,
French, R. R.,
and Glennie, M. J.
(1995)
J. Immunol. Methods
183,
51-63
29.
Gorgani, N. N.,
Parish, C. R.,
Easterbrook Smith, S. B.,
and Altin, J. G.
(1997)
Biochemistry
36,
6653-6662
30.
Kuhlenkamp, J.,
Ronk, M.,
Yusin, M.,
Stolz, A.,
and Kaplowitz, N.
(1993)
Protein Expression Purif.
4,
382-389
31.
Yoshida, H.,
Yusin, M.,
Ren, I.,
Kuhlenkamp, J.,
Hirano, T.,
Stolz, A.,
and Kaplowitz, N.
(1992)
J. Lipid Res.
33,
343-350
32.
Bateman, A.,
Birney, E.,
Durbin, R.,
Eddy, S. R.,
Finn, R. D.,
and Sonnhammer, E. L.
(1999)
Nucleic Acids Res.
27,
260-262
33.
Saxena, P.,
and Walker, J. R.
(1992)
J. Bacteriol.
174,
1956-1964
34.
Sha, B.,
Phillips, S. E.,
Bankaitis, V. A.,
and Luo, M.
(1998)
Nature
391,
506-510
35.
Merkulova, M. I.,
Andreeva, S. G.,
Shuvaeva, T. M.,
Novoselov, S. V.,
Peshenko, I. V.,
Bystrova, M. F.,
Novoselov, V. I.,
Fesenko, E. E.,
and Lipkin, V. M.
(1999)
FEBS Lett.
450,
126-130
36.
Arita, M.,
Sato, Y.,
Miyata, A.,
Tanabe, T.,
Takahashi, E.,
Kayden, H. J.,
Arai, H.,
and Inoue, K.
(1995)
Biochem. J.
306(Pt 2),
437-443
37.
Cockcroft, S.
(1998)
Bioessays
20,
423-432
38.
Phillips, S. E.,
Sha, B.,
Topalof, L.,
Xie, Z.,
Alb, J. G.,
Klenchin, V. A.,
Swigart, P.,
Cockcroft, S.,
Martin, T. F.,
Luo, M.,
and Bankaitis, V. A.
(1999)
Mol. Cell
4,
187-197
39.
Novoselov, V. I.,
Peshenko, I. V.,
Evdokimov, V. J.,
Nikolaev, J. V.,
Matveeva, E. A.,
and Fesenko, E. E.
(1994)
FEBS Lett.
353,
286-288
40.
Aravind, L.,
Neuwald, A. F.,
and Ponting, C. P.
(1999)
Curr. Biol.
9,
R195-R197
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. L. Goldstein, D. Glossip, S. Nayak, and K. Kornfeld The CRAL/TRIO and GOLD Domain Protein CGR-1 Promotes Induction of Vulval Cell Fates in Caenorhabditis elegans and Interacts Genetically With the Ras Signaling Pathway Genetics, February 1, 2006; 172(2): 929 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ni, X. Wen, J. Yao, H.-C. Chang, Y. Yin, M. Zhang, S. Xie, M. Chen, B. Simons, P. Chang, et al. Tocopherol-Associated Protein Suppresses Prostate Cancer Cell Growth by Inhibition of the Phosphoinositide 3-Kinase Pathway Cancer Res., November 1, 2005; 65(21): 9807 - 9816. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikeda, M. Murakami, and M. Funaba Expression of Tocopherol-Associated Protein in Mast Cells Clin. Vaccine Immunol., November 1, 2004; 11(6): 1189 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Singh, V. Mokashi, C. L. Elmore, and T. D. Porter Phosphorylation of Supernatant Protein Factor Enhances Its Ability to Stimulate Microsomal Squalene Monooxygenase J. Biol. Chem., February 14, 2003; 278(8): 5646 - 5651. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kolleck, P. Sinha, and B. Rustow Vitamin E as an Antioxidant of the Lung: Mechanisms of Vitamin E Delivery to Alveolar Type II Cells Am. J. Respir. C |